Treatment
Human Dopaminergic Progenitor Cells clinical trials
We’re tracking 7 recruiting studies that include Human Dopaminergic Progenitor Cells, each written for real people, not researchers, below.
Recruiting studies
- NCT06482268RecruitingPhase 1
Cell transplant for advanced parkinson's disease
This trial tests a new type of cell transplant for Parkinson's disease. The cells are made from stem cells and are meant to replace damaged brain cells that produce dopamine, which may improve your motor symptoms.
La Jolla, CaliforniaAges 40–75 - NCT07289477RecruitingPhase 1
Study of NouvNeu001 for Multiple System Atrophy
This study tests a new injection called NouvNeu001 for people with Multiple System Atrophy (MSA). The goal is to see if it can help control symptoms that standard treatments aren't managing well.
Beijing, Beijing MunicipalityAges 30–70 - NCT06167681RecruitingPhase 1/Phase 2
Cell Therapy NouvNeu001 for Parkinson's Disease
This trial tests a new cell therapy called NouvNeu001 for Parkinson's disease. It involves a one-time brain surgery to deliver the treatment, and researchers will check if it's safe and helps with symptoms.
Beijing, Beijing MunicipalityAges 50–75 - NCT06608355RecruitingPhase 1
Stem cell treatment for early-onset Parkinson's
This trial tests a new stem cell treatment called NouvNeu001 for people with early-onset Parkinson's disease. The goal is to see if it's safe and if it can help improve movement and daily life.
Wuhan, HubeiAges 18–70 - NCT07080775RecruitingPhase 1
Testing a new injection for Parkinson's disease
This trial tests an injection called XS411CN for people with Parkinson's disease whose current medications are not working as well as before. The goal is to see if it is safe and tolerable.
Beijing, Beijing MunicipalityAges 50–75 - NCT07102342RecruitingPhase 1/Phase 2
Cell therapy for Parkinson's disease
This trial tests a new cell treatment for Parkinson's disease. It involves injecting special cells into the brain to see if they can safely replace damaged cells and improve symptoms. It might help people who have had Parkinson's for several years and still respond well to medication.
New York, New YorkAges 30–75 - NCT07166757RecruitingPhase 1/Phase 2
Study of XS411 for early-onset Parkinson's disease
This trial tests a new treatment called XS411 for people with early-onset Parkinson's disease (age 50 or younger at diagnosis). It is for those whose motor symptoms are not well controlled with standard medications and who may benefit from a neurosurgical procedure.
Shanghai, Shanghai MunicipalityAges 18–70
What Human Dopaminergic Progenitor Cells is being studied for
Conditions with recruiting Human Dopaminergic Progenitor Cells studies.
Common questions
- Are there clinical trials studying Human Dopaminergic Progenitor Cells?
- Yes. Clin2 currently lists 7 recruiting studies that include Human Dopaminergic Progenitor Cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Human Dopaminergic Progenitor Cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Human Dopaminergic Progenitor Cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Human Dopaminergic Progenitor Cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.